[HTML][HTML] Epidemiology of peritoneal dialysis outcomes
Peritoneal dialysis (PD) is an important home-based treatment for kidney failure and
accounts for 11% of all dialysis and 9% of all kidney replacement therapy globally. Although …
accounts for 11% of all dialysis and 9% of all kidney replacement therapy globally. Although …
[HTML][HTML] Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update
The vascular endothelium is a dynamic, functionally complex organ, modulating multiple
biological processes, including vascular tone and permeability, inflammatory responses …
biological processes, including vascular tone and permeability, inflammatory responses …
Diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder: Synopsis of the kidney disease: improving global outcomes …
M Ketteler, GA Block, P Evenepoel… - Annals of internal …, 2018 - acpjournals.org
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical
Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of …
Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of …
[HTML][HTML] Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion
PP Centeno, A Herberger, HC Mun, C Tu… - Nature …, 2019 - nature.com
Extracellular phosphate regulates its own renal excretion by eliciting concentration-
dependent secretion of parathyroid hormone (PTH). However, the phosphate-sensing …
dependent secretion of parathyroid hormone (PTH). However, the phosphate-sensing …
Chronic kidney disease—mineral and bone disorders: pathogenesis and management
JB Cannata-Andía, B Martín-Carro… - Calcified tissue …, 2021 - Springer
The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …
Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and …
More than 2 million people worldwide are being treated for end-stage kidney disease
(ESKD). This Series paper provides an overview of incidence, modality use (in-centre …
(ESKD). This Series paper provides an overview of incidence, modality use (in-centre …
FGF23 and klotho at the intersection of kidney and cardiovascular disease
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease
(CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral …
(CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral …
Arterial calcification in chronic kidney disease: key roles for calcium and phosphate
Vascular calcification contributes to the high risk of cardiovascular mortality in chronic kidney
disease (CKD) patients. Dysregulation of calcium (Ca) and phosphate (P) metabolism is …
disease (CKD) patients. Dysregulation of calcium (Ca) and phosphate (P) metabolism is …
The heart and vascular system in dialysis
C Wanner, K Amann, T Shoji - The Lancet, 2016 - thelancet.com
The heart and the vascular tree undergo major structural and functional changes when
kidney function declines and renal replacement therapy is required. The many …
kidney function declines and renal replacement therapy is required. The many …
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS …
F Tentori, M Wang, BA Bieber… - Clinical Journal of the …, 2015 - journals.lww.com
Results Median parathyroid hormone increased from phase 1 to phase 4 in all regions
except for Japan, where it remained stable. Prescriptions of intravenous vitamin D analogs …
except for Japan, where it remained stable. Prescriptions of intravenous vitamin D analogs …